Latest Pathology News

Page 1 of 14
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Mach7 Technologies has completed a costly FY26 reset, cutting operating expenditure by 16% while revenue fell 17% and the net loss widened to A$8.9 million. The company enters FY27 with a higher recurring-revenue mix, new customer orders and A$19.9 million in cash, but no earnings guidance and plenty to prove.
Victor Sage
Victor Sage
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.
Ada Torres
Ada Torres
28 Oct 2026
Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.
Victor Sage
Victor Sage
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.
Victor Sage
Victor Sage
23 Oct 2026
Charter Hall Long WALE REIT has maintained its FY27 operating earnings and distribution guidance at 25.5 cents per security after delivering 2% FY26 growth. A cheaper, longer-dated debt platform and a $6.1 billion portfolio give the REIT more financial flexibility, although the outlook still depends on execution and property valuations.
Eva Park
Eva Park
15 Oct 2026
Spheria Emerging Companies reported a sharp fall in FY2026 profit after tax after its portfolio returned just 0.3%, well behind the 8.1% benchmark. Monthly fully franked dividends continue and the listed investment company avoided a conversion vote after trading at a premium to NTA.
Claire Turing
Claire Turing
14 Oct 2026
Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.
Victor Sage
Victor Sage
5 Oct 2026

Browse the archive

Full archive